EP 0680607 A4 19970604 - ASSAY METHOD TO RULE OUT RUPTURE OF MEMBRANES IN WOMEN AT RISK FOR IMMINENT DELIVERY.
Title (en)
ASSAY METHOD TO RULE OUT RUPTURE OF MEMBRANES IN WOMEN AT RISK FOR IMMINENT DELIVERY.
Title (de)
TESTVERFAHREN ZUR AUSSCHLUSS VON MEMBRANRISSEN ALS RISIKO BEI KURZ VOR DER ENTBINDUNG STEHENDEN FRAUEN.
Title (fr)
METHODE DE DOSAGE PERMETTANT D'IDENTIFIER LA RUPTURE DES MEMBRANES CHEZ LES FEMMES PRESENTANT UN RISQUE D'ACCOUCHEMENT IMMINENT.
Publication
Application
Priority
- US 9400455 W 19940121
- US 743293 A 19930122
Abstract (en)
[origin: WO9417405A1] The present invention provides an assay that distinguishes those patients with impending imminent delivery with intact membranes from those in whom the membranes have ruptured. The method comprises obtaining a cervicovaginal secretion sample from a pregnant patient determined to be as at risk for imminent delivery by detection of a biochemical marker for imminent delivery in a cervicovaginal secretion sample from the patient and determining the level of IGFBP-1 in the sample. If the level of IGFBP-1 is elevated, the patient has rupture of membranes. If IGFBP-1 is not present, the patient has intact membranes. In a preferred embodiment, the method comprises obtaining a cervicovaginal secretion sample from a pregnant patient after about week 20 of gestation and determining the level of fetal fibronectin and IGFBP-1 in the sample. The presence of an elevated fibronectin level in the sample indicates an increased risk of imminent delivery. If the level of IGFBP-1 is elevated, the patient had rupture of membranes. If IGFBP-1 is not present, the patient has intact membranes. If IGFBP-1 is not present, the IGFBP-1 assay is preferably repeated. In those patients with an increased level of IGFBP-1, the test indicates that delivery cannot be delayed.
IPC 1-7
IPC 8 full level
G01N 33/53 (2006.01); C07K 16/18 (2006.01); C12N 15/09 (2006.01); C12Q 1/02 (2006.01); C12Q 1/37 (2006.01); G01N 33/573 (2006.01); G01N 33/68 (2006.01)
CPC (source: EP)
C07K 16/18 (2013.01); G01N 33/689 (2013.01); G01N 2333/78 (2013.01); G01N 2800/368 (2013.01)
Citation (search report)
- [A] S.L.S. DROP ET AL.: "Isolation of a somatomedin-binding protein from preterm amniotic fluid.", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 59, no. 5, 1984, WASHINGTON DC USA, pages 899 - 907, XP000646852
- [A] M. FANT: "Insulin-like growth factor binding proteins (BP) from human placenta are immunologically related to the growth hormone dependent binding protein in adult human serum (BP-53).", PLACENTA, vol. 11, no. 2, 1990, DALLAS TY USA, pages 123 - 133, XP000646849
- [AP] H.S. WANG ET AL.: "Levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-1 in pregnancy with preterm delivery", BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, vol. 100, no. 5, 1 May 1993 (1993-05-01), OXFORD UK, pages 472 - 475, XP000646845
- See references of WO 9417405A1
Designated contracting state (EPC)
DE ES FR GB IT
DOCDB simple family (publication)
WO 9417405 A1 19940804; CA 2152676 A1 19940804; EP 0680607 A1 19951108; EP 0680607 A4 19970604; JP 2004125807 A 20040422; JP 2005326427 A 20051124; JP 3742649 B2 20060208; JP 3943575 B2 20070711; JP H08506658 A 19960716
DOCDB simple family (application)
US 9400455 W 19940121; CA 2152676 A 19940121; EP 94906621 A 19940121; JP 2003412234 A 20031210; JP 2005175366 A 20050615; JP 51709594 A 19940121